ChronTech Pharma AB: ChronTech Receives a Six Months’ Extension of Its Option to Buy Back in ChronSeal®

STOCKHOLM--(BUSINESS WIRE)-- As a consequence of that the results of the ChronSeal® study will not be made public until May 27th Kringle Inc. in Japan has given ChronTech Pharma (STO:CTEC) a six months’ extension, i.e. until the 31st of December 2010, of its option to buy back in ownership of the ChronSeal®.

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

This information was brought to you by Cision http://www.cisionwire.com



CONTACT:

ChronTech Pharma AB
Anders Vahlne, +46 8 5858 1313
CEO and Head of Research
Mobile phone: +46 709 28 05 28
[email protected]

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  Other Health  Medical Supplies

MEDIA:

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.